PI-103 in Chordoma

Joseph Schwab, Cristina Antonescu, John Healey, Patrick Boland, G. Petur Nielsen, Andrew Rosenberg, Edwin Choy, David Harmon, Thomas DeLaney, Cao Yang, Francis Hornicek, Zhenfeng Duan

MGH Chordoma Research GroupMemorial Sloan Kettering Cancer CenterDF/Harvard Cancer Center

PI3K/mTOR inhibition with PI-103 in Chordoma

PI-103 in Chordoma

Chordoma Background

• Low Grade Malignancy of the Axial Spine

• Surgery remains the standard of care

• Local Recurrence 40 to 60% – Fuchs et al JBJS 2005, Bergh et al Cancer 2000 Samson et al JBJS 1993,

Schwab et al under review

• Metastasis >30% – Fuchs et al JBJS 2005, Bergh et al Cancer 2000, Samson et al JBJS 1993,

Schwab et al under review

PI-103 in Chordoma

Background

• No effective systemic therapy exists for chordoma

• PI-103 dual PI3k(class 1a)/mTOR inhibitor• Inhibits glioma growth Fan et al, Cancer Cell 2006

• Sensitized PTEN-mutant glioma cells to EGFR inhibition Fan et al Cancer Res 2007

• Sensitizes Glioblastoma to radiation (Chen et al, Mol

Cancer Ther 2008)

• Induces apoptosis and sensitized Leukemic cells (AML) to chemotherapy (Park et al, Leukemia 2008)

PI-103 in Chordoma

PI-103

PI-103 in Chordoma

Specific Aims

• #1 Establish the presence of the PI3K/mTOR pathway in human chordoma tissue

• #2 Demonstrate the efficacy of PI-103 in a human chordoma cell line with regard to proliferation and apoptosis

• #3 To determine the effects of PI-103 when combined with conventional chemotherapeutic agents doxorubicin and cisplatin

PI-103 in Chordoma

Methods

• Western blot analysis of PDK, AKT, mTOR and S6 in human chordoma specimen

• PI-103 0.1μM, 1 μM, 5 μM, 10 μM human chordoma cell line UCH-1

• Western blot analysis of phosho-AKT and phosho-mTOR post PI-103

• Proliferation and apoptosis assays in UCH-1 post PI-103

• Apoptosis assay in UCH-1 post PI-103 with doxorubicin or cisplatin

PI-103 in Chordoma

PI-103 in Chordoma

pmTOR

mTOR

pAKT

AKT

BcL-XL

pStat3

Brachyury

β-Actin

PI-103 (μM) 0.01 0.05 0.1 0.5 1 50

PI-103 in Chordoma

PI-103 and Decreased Chordoma Proliferation

PI-103 in Chordoma

PI-103 Increases Chordoma Cell Apoptosis

PI-103 in Chordoma

PI-103 increases apoptosis with Doxorubicin and Cisplatin

PI-103 in Chordoma

Conclusion

• #1 PI3K/mTOR pathway is active in human chordoma

• #2 PI-103 inhibits the activation of AKT and mTOR in vitro

• #3 PI-103 reduces proliferation and induces apoptosis of a human chordoma cell line

• #4 PI-103 seems to sensitize human chordoma cells to doxorubicin and cisplatin in vitro

PI-103 in Chordoma

PI3K/mTOR inhibition with PI-103 in Chordoma

• Thank You